H trial-and-error. Pharmacogenomics has the potential to individualize antihypertensive drug therapy and lead to better BP control and improve the long-term outcomes of those with hypertension.
Among all individuals in the United States over age 65 years, ≈32% are prescribed a β-blocker.
8 β-blockers are often viewed as a suboptimal antihypertensive choice in African Americans overall, despite recognition that BP response to any single antihypertensive drug is characterized by large interindividual variation. 9, 10 In this study, we performed the first pharmacogenomic genome-wide meta-analysis of BP response to β-blockers in African Americans to shed light on pharmacogenomic signals that may explain this observed variability in response.
Methods

Study Participants
The Pharmacogenomic Evaluation of Antihypertensive Responses: PEAR-1 and PEAR-2 Studies
The Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)-1 study (clinicaltrials.gov identifier NCT00246519) was a multicenter randomized controlled clinical trial evaluating genetic determinants of BP responses to atenolol and hydrochlorothiazide monotherapy and combination therapy of the drugs. 11 The PEAR-2 study was a multicenter sequential monotherapy clinical trial (clinicaltrials.gov identifier NCT01203852) 12 evaluating genetic determinants of BP response to metoprolol monotherapy and chlorthalidone monotherapy. Both PEAR-1 and PEAR-2 studies included individuals with mild to moderate essential hypertension. Individuals with diabetes mellitus and known cardiovascular disease were excluded. The details of these 2 studies are summarized in the online-only Data Supplement. The study protocols for both the PEAR-1 and PEAR-2 studies were reviewed and approved by the Institutional Review Boards at all sites recruiting subjects (University of Florida, Gainesville, FL; Emory University, Atlanta, GA; Mayo Clinic, Rochester, MN; and East Coast Institute for Research, Jacksonville, FL [PEAR-2 only]), and all participants provided voluntary, written informed consent before participation. This analysis focuses on the African American BP response to atenolol monotherapy and add-on therapy in the PEAR-1 study and the BP response to metoprolol monotherapy in the PEAR-2 study.
Blood Pressure Phenotype
In the PEAR-1 study, BP was measured using 3 different methods: home, office, and ambulatory. 11 For genome-wide association analysis, we used the most precise phenotype available, which is a composite-weighted average of the office, home, ambulatory daytime and nighttime BP responses calculated based on the row sums of the inverse of the inter-method covariance matrices. 13 This weighted average BP had higher signal-to-noise ratio and, therefore, provides greater power to detect genetic differences compared with any single component measurement of the composite BP response phenotype. 13 In the PEAR-2 study, home and office BP measurements were collected. We have previously demonstrated that home BP is the more informative single BP measurement compared with the office BP measurement. 13 Therefore, home BP is the phenotype used for the genome-wide association analysis for PEAR-2. We have demonstrated 13 that different methods of measuring BP response to antihypertensive drug therapy detect the same signal but with different signal-to-noise ratios. This allows us to perform the meta-analysis of PEAR-1 and PEAR-2 to identify the real BP response signal.
Genotyping and Imputation
The details on the genome-wide genotyping, quality control, and imputation performed on PEAR-1 and PEAR-2 participants are presented in the online-only Data Supplement.
Statistical Analysis
Continuous variables were presented as mean and standard deviation, and categorical variables were presented as numbers and percentages. t Test, Wilcoxon rank-sum test, or chi-square test were used to compare the individuals treated with atenolol or metoprolol monotherapy as appropriate. Spearman correlation was performed between baseline plasma renin activity (PRA) and BP response. Genome-wide association analysis for BP response was performed in African American hypertensive patients treated with atenolol monotherapy (n=150) and metoprolol monotherapy (n=168) separately. Multiple linear regression analyses were performed adjusting for baseline BP, age, sex, and the first 2 principal components for ancestry. Variables such as body mass index and smoking were evaluated but were not associated with the BP response and, therefore, not included in the regression models. The additive mode of inheritance was assumed, where imputed dosages of the single nucleotide polymorphisms (SNPs) were used in the linear regression models. Meta-analysis of monotherapy response was then performed using Meta Analysis Helper (METAL).
14 SNPs with P<5×10 -8 were considered genome-wide significant, and those with P<5×10 -7 were considered suggestive. To validate the genomewide significant and the suggestive SNPs in an independent group of participants, we assessed the association of these SNPs and BP response in PEAR-1 African American participants treated with atenolol add-on therapy (n=141). We considered SNPs with P<0.05 with same direction of association as was observed in the monotherapy analysis to be validated and performed 3-group meta-analysis for the SNPs that achieved that level. As a sensitivity analysis, the association was also adjusted for pretreatment PRA.
Results
The relevant baseline characteristics of the African American participants treated with atenolol monotherapy and those treated with metoprolol monotherapy are summarized in Table 1 . The participants treated with atenolol monotherapy were significantly younger (47 versus 50 years old on average) than those treated with metoprolol (P=0.006). Atenolol-treated participants were predominantly female (71%), whereas females represented 53% of those treated with metoprolol (P=0.0008). The pretreatment BP (145.1/93.9 mm Hg) in the atenolol group was lower than in the metoprolol group (147.5/95.6 mm Hg; P=0.045/0.017). The baseline PRA was similar between atenolol monotherapy (median of 0.37 ng/mL per hour) and metoprolol monotherapy (median of 0.41 ng/mL per hour).
BP Response to Atenolol and Metoprolol
In the PEAR-1 study, the median length of atenolol monotherapy was 70 days (with interquartile range of 64-77days). Eighty-nine percent of patients had the atenolol dose titrated to 100 mg/day; in those who did not have the dose titrated from 50 mg/day, the most common reason was a heart rate <55 bpm. The mean BP response was −3.2/−4.2 mm Hg after atenolol monotherapy. There was no significant difference in BP response between those treated with higher dose (−3. In the PEAR-2 study, ≈96% of the patients had their metoprolol dose titrated, and the median length of monotherapy was 58 days (interquartile range: 56-64 days). The average BP response was −4.7/−5.8 mm Hg after metoprolol monotherapy. Similar to response to atenolol, the BP response was not correlated with the length of the treatment (P=0.77 for SBP response and P=0.66 for DBP response) or the dose of metoprolol (P=0.39 for SBP response and P=0.11 for DBP response). Figure 1 demonstrates the substantial interindividual variability in BP response to both atenolol and metoprolol observed in our African American hypertensive participants. Although the average SBP reduction was around 3-5 mm Hg, ≈26% and 32% of the African American participants had a >10 mm Hg SBP reduction in response to atenolol and metoprolol, respectively.
In both groups of individuals treated with atenolol monotherapy and metoprolol monotherapy, the BP response was negatively correlated with the baseline PRA. The Spearman correlation coefficients were −0. 
Genome-Wide Analysis of BP Response to β-Blockers in African Americans
SNPs associated with BP response to atenolol in the genomewide analysis with suggestive significance (P<5×10 -7 ) are listed in Table S1 in the online-only Data Supplement. One SNP (rs61128812) on Chromosome 20p12.1 reached genomewide significance, with P=1.68×10 -8 for association with DBP response to atenolol. Top SNPs associated with BP response to metoprolol are summarized in Table S2 . One insertion/deletion variant (rs138781672) on chromosome 12 was associated with SBP response to metoprolol with P=2.76×10 -8 , which also achieved genome-wide significance.
In the meta-analysis of BP response to atenolol or metoprolol monotherapy, 1 SNP was genome-wide significant with P<5×10 -8 . The Manhattan plots are shown in Figure  S1 . The SNPs with P<5×10 -7 are summarized in Table 2 for DBP response and Table 3 for SBP response, which represented 8 unique signals/regions. An intronic SNP, rs1367094 in the ZMAT4 (zinc finger matrix type 4) gene was associated DBP response to β-blocker monotherapy (meta-analysis P=2.82×10 -8 ; Figure S2 ). African American hypertensive participants with the TT genotype of rs1367094 had a DBP response of −6.0 mm Hg when treated with atenolol and −6.6 mm Hg when treated with metoprolol, whereas those with CT genotype had +1.1 mm Hg in response to atenolol and −2.3 mm Hg in response to metoprolol (P=1.62×10 -6 for atenolol and 0.0027 for metoprolol; Figure S3 ). This SNP was also associated with SBP response to these specific β-blockers in the meta-analysis (P=1.55×10 -7 ; Table 3 ).
Validation in BP Response to Atenolol Add-On Therapy
To validate the association of the SNPs in an independent patient group, we evaluated the association of the suggestive SNPs/regions (8 regions for DBP association and 8 regions for SBP association, respectively) in the only available African American β-blocker-treated clinical trial cohort, to our knowledge: the 141 African Americans hypertensive patients in PEAR study who had atenolol added to hydrochlorothiazide monotherapy (demographics presented in Table 1 ).
The ZMAT4 SNP (rs1367094) that reached genome-wide significance in African American DBP response association in the monotherapy meta-analysis was not associated with the BP response to the atenolol add-on therapy. The P value was 0.71 for rs1367094 in DBP response to atenolol add-on therapy, with a β of −0.37 mm Hg/allele, the same direction as One variant (rs201279313) in the SLC25A31 gene was validated in the DBP response to the atenolol add-on therapy with the same direction of effect compared with the monotherapy group. The regional plot of this variant is shown in Figure  S4 . This variant is a deletion of TTA in the intronic region. The deletion allele was associated with greater BP reduction after β-blocker treatment. In the African American participants treated with atenolol monotherapy, those with the heterozygous genotype had a DBP response of −9.3 mm Hg compared with −4.6 mm Hg in those with the wild-type genotype of this variant (P=5.8×10 -4 ). The DBP responses to metoprolol monotherapy were −9.6 and −4.8 mm Hg in heterozygous and wild-type participants, respectively (P=5.3×10 -5 ). In the atenolol add-on therapy, the DBP responses were −9.7 versus −6.4 mm Hg for the heterozygotes and wild-type individuals, respectively (P=0.033). The meta-analysis of the atenolol monotherapy, metoprolol monotherapy, and atenolol add-on therapy yielded P value of 2.5×10 -8 and β of −4.42 mm Hg per deletion allele (Figure 2 ). The P value of meta-analysis remained significant (4.81×10 -8 ) after controlling for pretreatment PRA.
Likewise, one variant was validated for SBP response in the atenolol add-on therapy. The deletion allele of rs11313667 (C/−, MAF=16%), located in the intronic region of LRRC15 gene on chromosome 3 (regional plot shown in Figure S5 ), was associated with better SBP response to β-blocker monotherapy (β=−4.9 mm Hg; P=1.49×10 ) and was nominally associated with better SBP response to atenolol add-on therapy (β=−2.3 mm Hg; P=0.023). The P value for the 3-group meta-analysis was 7.16×10 -8 with a β of −3.65 mm Hg per deletion allele ( Figure 3) . After controlling for pretreatment PRA, the P value for the meta-analysis was slightly weaker (1.58×10
-7
).
Discussion
This is the first pharmacogenomic genome-wide association study of BP response to β-blockers reported in African American hypertensive patients. Two variants that were selected for follow-up based on meta-analysis of responses to atenolol and metoprolol were validated in the analysis of African American hypertensive participants treated with atenolol add-on therapy, with meta-analysis P value of one achieving genome-wide significance. The variants were both deletion alleles, rs201279313 in SLC25A31 for DBP response (P=2.5×10 -8 in the 3-group meta-analysis) and rs11313667 in LRRC15 for SBP response (P=7.2×10 -8 in the 3-group metaanalysis). We also identified 1 SNP with genome-wide significance in the meta-analysis of BP response to β-blocker monotherapy: rs1367094 (an intronic SNP in gene ZMAT4) for DBP response, but this SNP was not validated when tested in the atenolol add-on therapy cohort.
Atenolol and metoprolol are both cardioselective β-blockers that block the action of the sympathetic nervous system, in particular on β1 adrenergic receptors (β1 adrenoceptors) that are mainly expressed in the heart and kidneys. β-blockers are often overlooked as potent suppressors of renin secretion and presumably of angiotensin II formation. 15 Sympathetic nervous system activation is usually accompanied by increased renin secretion. 16 Accordingly, the BP lowering of β-blockers is greatest in patients with high PRA and least in those with low PRA. [17] [18] [19] Hypertensive patients of African descent on average have lower PRA and, therefore, less BP lowering when treated with β-blockers compared with those of European ancestry. 20 However, we have shown that 20%-30% of African Americans, hypertensive participants responded well to β-blocker treatment. Consistent with prior reports, we found that those with higher baseline PRA responded better to atenolol or metoprolol. This highlights that β-blocker therapy can be a very effective antihypertensive drug class for a portion of African Americans. Identifying these patients a priori (based on not only PRA but also independent genetic variants) could provide valuable information on the optimal antihypertensive treatment for this group of African Americans.
In this genome-wide analysis study, 2 variants were validated across 3 cohorts (and 2 β-blockers) as associated with BP response to β-blockers, one associated with DBP response and the other associated with SBP response. The variant rs201279313 that was validated for DBP response is the deletion of a TTA in the intronic region of SLC25A31, solute carrier family 25 member 31, on chromosome 4q28.1. The SLC25A31 gene encodes ADP/ATP translocase 4, which inhibits apoptosis by catalyzing ADP/ATP exchange across the mitochondrial membranes, regulating membrane potential. 21 To date, there is no evidence of SLC25A31 gene mutations being associated with a human disease. 22 Other genes in this region include INTU (inturned planar cell polarity protein), HSPA4L (heat shock 70 kDa protein 4-like), PLK4 (polo-like kinase 4), MFSD8 (major facilitator superfamily domain containing 8), and LARP1B (La ribonucleoprotein domain family, member 1B). It is not immediately clear how this variant could be involved with response to BP response to β-blockers. The HaploReg database 23 indicates that there is no other variant in high linkage disequilibrium with this variant in African populations in the 1000 Genomes database, and this variant was found to alter 14 regulatory motifs, including Evi-1_4, Fox, and HDAC2_disc6. Further study is warranted to understand the functional underpinning of this association.
The variant validated for SBP response to β-blockers, rs11313667, is an insertion/deletion variant (C/−) in the intronic region of LRRC15 (leucine-rich repeat containing 15) gene. In the 1000 Genomes African populations, this variant is in high linkage disequilibrium with 3 synonymous SNPs in the same gene: rs4974533 (r2=0.8, D′=−0.97), rs9682540 (r 2 =0.82 and D′=−0.98), and rs923935 (r 2 =0.8, D′=−0.97). Synonymous SNPs have been found to affect mRNA splicing, stability, and structure as well as protein folding. 24 LRRC15 is a tumor antigen, a cell surface glycoprotein normally expressed only in the invasive cytotrophoblast layer of the placenta, and it was found to be overly expressed in the androgen-independent metastatic prostate cancer. 25 There is no apparent link between LRRC15 and BP in the literature. Other genes in this region include CPN2, GP5, and ATP13A3. The most potentially interesting gene in this region related to BP is GP5 encoding platelet glycoprotein V, which mediates the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis. Soluble platelet glycoprotein V is a plasma marker of thrombosis released from the platelet surface by thrombin and was found to be a marker of thrombosis in patients with ischemic stroke. 26 Hypertension is a major risk factor for thrombotic events, such as myocardial infraction and stroke, reflecting a prothrombotic state that is present in hypertensive patients. There is evidence that this prothrombolitic state can be induced by the activated renin-angiotensin system. 27 A study by Remkova et al demonstrated that soluble platelet glycoprotein V level was elevated in hypertensive patients compared with healthy individuals, and more importantly, treatment with the angiotensin-converting enzyme inhibitor perindopril (but not the angiotensin II receptor blocker telmisartan) significantly decreased the level of platelet glycoprotein V in hypertensive individuals. 28 It is plausible that β-blockers, as suppressors of renin secretion, could be involved with expression of platelet glycoprotein V. We observed that the association of this variant was only slightly weaker after adjusting for baseline PRA, indicating that a very small portion of this association might be explained by PRA, but essentially, the mechanism of this association remains to be elucidated. It is important to carry out further functional studies to elucidate the mechanisms of these findings.
We acknowledge at least 2 limitations of this study. First, we recognize that the BP response to add-on therapy may not be the optimal validation for association with BP response to β-blocker monotherapy, and lack of association in the add-on therapy should not be regarded as evidence to dismiss their association with the BP response to the monotherapy. One potential reason that the significant SNP in the β-blocker monotherapy was not validated in the add-on therapy is that the pretreatment PRA was much higher compared with those in the monotherapy as a result of hydrochlorothiazide monotherapy, which is known to increase PRA. Even though our sensitivity analysis that adjust for pretreatment PRA did not show different results, it is possible that statistical adjustment might not be sufficient to control for such difference. Thus, in particular, the variant that achieved genome-wide significance in the monotherapy meta-analysis remains of interest. Second, both PEAR-1 and PEAR-2 studies have active treatment for all arms; the phenotype of change in BP might not be easy to interpret without a placebo run-in or double blind cross-over design. In conclusion, we performed the first genome-wide meta-analysis of BP response to β-blockers in hypertensive African American individuals and identified several potentially important variants that deserve additional study. Further investigation regarding the functional underpinning of these associations could advance our current understanding of β-blocker use in African Americans and potentially serve as a basis of precision medicine in treating hypertension in this special group of individuals.
Perspectives
Hypertension is the most important risk factor for global disease burden, and it is particularly problematic in African Americans. Hypertension is also the most common chronic disease for which medications are prescribed. Pharmacogenomics offers the clinical promise of individualized antihypertensive therapy on the basis of matching a patient's genetic makeup and the pharmacological action of the drugs prescribed. This study performed the first pharmacogenomic genome-wide association study of BP response to β-blockers in African American hypertensive individuals and identified 2 variants that were validated across 3 different cohorts, with clinically relevant differences in BP response by genotype. Further investigations of the 2 associated regions may provide valuable information for personalized antihypertensive treatment in African Americans. A.
